Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 242

1.

Structure and Reactivity of Half-Sandwich Rh(+3) and Ir(+3) Carbene Complexes. Catalytic Metathesis of Azobenzene Derivatives.

Tindall DJ, Werlé C, Goddard R, Philipps P, Farès C, Fürstner A.

J Am Chem Soc. 2018 Feb 7;140(5):1884-1893. doi: 10.1021/jacs.7b12673. Epub 2018 Jan 29.

PMID:
29332395
2.

Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer.

He Y, Lu J, Ye Z, Hao S, Wang L, Kohli M, Tindall DJ, Li B, Zhu R, Wang L, Huang H.

Nucleic Acids Res. 2018 Feb 28;46(4):1895-1911. doi: 10.1093/nar/gkx1306.

3.

Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer.

Zhao Y, Wang L, Ren S, Wang L, Blackburn PR, McNulty MS, Gao X, Qiao M, Vessella RL, Kohli M, Zhang J, Karnes RJ, Tindall DJ, Kim Y, MacLeod R, Ekker SC, Kang T, Sun Y, Huang H.

Cell Rep. 2016 Apr 19;15(3):599-610. doi: 10.1016/j.celrep.2016.03.038. Epub 2016 Apr 7.

4.

Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation.

Spratt DE, Evans MJ, Davis BJ, Doran MG, Lee MX, Shah N, Wongvipat J, Carnazza KE, Klee GG, Polkinghorn W, Tindall DJ, Lewis JS, Sawyers CL.

Cancer Res. 2015 Nov 15;75(22):4688-96. doi: 10.1158/0008-5472.CAN-15-0892. Epub 2015 Oct 2.

5.

Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer.

Kohli M, Young CY, Tindall DJ, Nandy D, McKenzie KM, Bevan GH, Donkena KV.

Onco Targets Ther. 2015 Jul 30;8:1915-22. doi: 10.2147/OTT.S86637. eCollection 2015.

6.

Are androgen receptor variants a substitute for the full-length receptor?

Lu J, Van der Steen T, Tindall DJ.

Nat Rev Urol. 2015 Mar;12(3):137-44. doi: 10.1038/nrurol.2015.13. Epub 2015 Feb 10. Review.

PMID:
25666893
7.

Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31.

Zhang Q, Padi SK, Tindall DJ, Guo B.

Cell Death Dis. 2014 Oct 23;5:e1486. doi: 10.1038/cddis.2014.454.

8.

Introduction to manuscript by Prof. Donald S. Coffey.

Tindall DJ.

Asian J Urol. 2014 Oct;1(1):2. doi: 10.1016/j.ajur.2015.04.002. Epub 2015 Apr 16. No abstract available.

9.

The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells.

Lu J, Lonergan PE, Nacusi LP, Wang L, Schmidt LJ, Sun Z, Van der Steen T, Boorjian SA, Kosari F, Vasmatzis G, Klee GG, Balk SP, Huang H, Wang C, Tindall DJ.

J Urol. 2015 Feb;193(2):690-8. doi: 10.1016/j.juro.2014.08.043. Epub 2014 Aug 14.

10.

Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer.

Zhao Y, Tindall DJ, Huang H.

Int J Biol Sci. 2014 Jun 5;10(6):614-9. doi: 10.7150/ijbs.8389. eCollection 2014. Review.

11.

Modeling and analysis of Gleason score 8-10 prostate cancers in the REDUCE study.

Andriole GL, Bostwick DG, Gomella LG, Marberger M, Montorsi F, Tammela TL, Tindall DJ, Fowler IL, Garges HP, Wilson TH, Castro R.

Urology. 2014 Aug;84(2):393-9. doi: 10.1016/j.urology.2014.04.016. Epub 2014 Jun 7.

PMID:
24916669
12.

Preclinical evaluation of the supercritical extract of azadirachta indica (neem) leaves in vitro and in vivo on inhibition of prostate cancer tumor growth.

Wu Q, Kohli M, Bergen HR 3rd, Cheville JC, Karnes RJ, Cao H, Young CY, Tindall DJ, McNiven MA, Donkena KV.

Mol Cancer Ther. 2014 May;13(5):1067-77. doi: 10.1158/1535-7163.MCT-13-0699. Epub 2014 Mar 27.

13.

Analyzing site selectivity in Rh2(esp)2-catalyzed intermolecular C-H amination reactions.

Bess EN, DeLuca RJ, Tindall DJ, Oderinde MS, Roizen JL, Du Bois J, Sigman MS.

J Am Chem Soc. 2014 Apr 16;136(15):5783-9. doi: 10.1021/ja5015508. Epub 2014 Apr 8.

14.

CBP loss cooperates with PTEN haploinsufficiency to drive prostate cancer: implications for epigenetic therapy.

Ding L, Chen S, Liu P, Pan Y, Zhong J, Regan KM, Wang L, Yu C, Rizzardi A, Cheng L, Zhang J, Schmechel SC, Cheville JC, Van Deursen J, Tindall DJ, Huang H.

Cancer Res. 2014 Apr 1;74(7):2050-61. doi: 10.1158/0008-5472.CAN-13-1659. Epub 2014 Feb 3.

15.

p300 acetyltransferase regulates androgen receptor degradation and PTEN-deficient prostate tumorigenesis.

Zhong J, Ding L, Bohrer LR, Pan Y, Liu P, Zhang J, Sebo TJ, Karnes RJ, Tindall DJ, van Deursen J, Huang H.

Cancer Res. 2014 Mar 15;74(6):1870-1880. doi: 10.1158/0008-5472.CAN-13-2485. Epub 2014 Jan 30.

16.

Imidazolidin-2-one: pseudosymmetry and twinning.

Taouss C, Jones PG, Tindall DJ.

Acta Crystallogr C. 2013 Dec 15;69(Pt 12):1534-6. doi: 10.1107/S0108270113030746. Epub 2013 Nov 15.

PMID:
24311506
17.

Posttranslational modification of the androgen receptor in prostate cancer.

van der Steen T, Tindall DJ, Huang H.

Int J Mol Sci. 2013 Jul 16;14(7):14833-59. doi: 10.3390/ijms140714833. Review.

18.

Androgen receptor: past, present and future.

Schmidt LJ, Tindall DJ.

Curr Drug Targets. 2013 Apr;14(4):401-7.

PMID:
23565753
19.

Androgens regulate TRAIL-induced cell death in prostate cancer cells via multiple mechanisms.

Wang D, Lu J, Tindall DJ.

Cancer Lett. 2013 Jul 10;335(1):136-44. doi: 10.1016/j.canlet.2013.02.001. Epub 2013 Feb 9.

20.

Autophagy control by the VEGF-C/NRP-2 axis in cancer and its implication for treatment resistance.

Stanton MJ, Dutta S, Zhang H, Polavaram NS, Leontovich AA, Hönscheid P, Sinicrope FA, Tindall DJ, Muders MH, Datta K.

Cancer Res. 2013 Jan 1;73(1):160-71. doi: 10.1158/0008-5472.CAN-11-3635. Epub 2012 Nov 13.

21.

Global methylation profiling for risk prediction of prostate cancer.

Mahapatra S, Klee EW, Young CY, Sun Z, Jimenez RE, Klee GG, Tindall DJ, Donkena KV.

Clin Cancer Res. 2012 May 15;18(10):2882-95. doi: 10.1158/1078-0432.CCR-11-2090.

22.

Antiangiogenic Effects and Therapeutic Targets of Azadirachta indica Leaf Extract in Endothelial Cells.

Mahapatra S, Young CY, Kohli M, Karnes RJ, Klee EW, Holmes MW, Tindall DJ, Donkena KV.

Evid Based Complement Alternat Med. 2012;2012:303019. doi: 10.1155/2012/303019. Epub 2012 Feb 22.

23.

RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.

Schmidt LJ, Duncan K, Yadav N, Regan KM, Verone AR, Lohse CM, Pop EA, Attwood K, Wilding G, Mohler JL, Sebo TJ, Tindall DJ, Heemers HV.

Mol Endocrinol. 2012 May;26(5):716-35. doi: 10.1210/me.2011-1130. Epub 2012 Mar 28.

24.

Dihydrotestosterone synthesis from adrenal precursors does not involve testosterone in castration-resistant prostate cancer.

Campbell TJ, Tindall DJ, Figg WD.

Cancer Biol Ther. 2012 Mar;13(5):237-8. doi: 10.4161/cbt.19608. Epub 2012 Mar 1.

25.

Androgen receptor signaling in prostate cancer development and progression.

Lonergan PE, Tindall DJ.

J Carcinog. 2011;10:20. doi: 10.4103/1477-3163.83937. Epub 2011 Aug 23.

26.

Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically.

Ryan CJ, Tindall DJ.

J Clin Oncol. 2011 Sep 20;29(27):3651-8. doi: 10.1200/JCO.2011.35.2005. Epub 2011 Aug 22. Review.

PMID:
21859989
27.

Androgen action during prostate carcinogenesis.

Wang D, Tindall DJ.

Methods Mol Biol. 2011;776:25-44. doi: 10.1007/978-1-61779-243-4_2. Review.

PMID:
21796518
28.

Alternatively spliced androgen receptor variants.

Dehm SM, Tindall DJ.

Endocr Relat Cancer. 2011 Sep 20;18(5):R183-96. doi: 10.1530/ERC-11-0141. Print 2011 Oct. Review.

29.

Androgen action in prostate cancer.

Basu S, Tindall DJ.

Horm Cancer. 2010 Oct;1(5):223-8. doi: 10.1007/s12672-010-0044-4. Review.

PMID:
21761368
30.

Androgens repress expression of the F-box protein Skp2 via p107 dependent and independent mechanisms in LNCaP prostate cancer cells.

Jiang J, Pan Y, Regan KM, Wu C, Zhang X, Tindall DJ, Huang H.

Prostate. 2012 Feb 1;72(2):225-32. doi: 10.1002/pros.21430. Epub 2011 May 31.

31.

Use of tumor dynamics to clarify the observed variability among biochemical recurrence nomograms for prostate cancer.

Dimonte G, Bergstralh EJ, Bolander ME, Karnes RJ, Tindall DJ.

Prostate. 2012 Feb;72(3):280-90. doi: 10.1002/pros.21429. Epub 2011 May 31.

32.

Targeting 5α-reductase for prostate cancer prevention and treatment.

Nacusi LP, Tindall DJ.

Nat Rev Urol. 2011 May 31;8(7):378-84. doi: 10.1038/nrurol.2011.67. Review.

33.

Novel molecular targets of Azadirachta indica associated with inhibition of tumor growth in prostate cancer.

Mahapatra S, Karnes RJ, Holmes MW, Young CY, Cheville JC, Kohli M, Klee EW, Tindall DJ, Donkena KV.

AAPS J. 2011 Sep;13(3):365-77. doi: 10.1208/s12248-011-9279-4. Epub 2011 May 11.

34.

Minireview: Alternative activation pathways for the androgen receptor in prostate cancer.

Lamont KR, Tindall DJ.

Mol Endocrinol. 2011 Jun;25(6):897-907. doi: 10.1210/me.2010-0469. Epub 2011 Mar 24. Review.

35.

Identification of a clinically relevant androgen-dependent gene signature in prostate cancer.

Heemers HV, Schmidt LJ, Sun Z, Regan KM, Anderson SK, Duncan K, Wang D, Liu S, Ballman KV, Tindall DJ.

Cancer Res. 2011 Mar 1;71(5):1978-88. doi: 10.1158/0008-5472.CAN-10-2512. Epub 2011 Feb 15.

36.

Regulation of FOXO protein stability via ubiquitination and proteasome degradation.

Huang H, Tindall DJ.

Biochim Biophys Acta. 2011 Nov;1813(11):1961-4. doi: 10.1016/j.bbamcr.2011.01.007. Epub 2011 Jan 14. Review.

37.

Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer.

Schmidt LJ, Tindall DJ.

J Steroid Biochem Mol Biol. 2011 May;125(1-2):32-8. doi: 10.1016/j.jsbmb.2010.09.003. Epub 2010 Sep 29. Review.

PMID:
20883781
38.

Oxidative stress and DNA methylation in prostate cancer.

Donkena KV, Young CY, Tindall DJ.

Obstet Gynecol Int. 2010;2010:302051. doi: 10.1155/2010/302051. Epub 2010 Jun 29.

39.

Mechanism of lymph node metastasis in prostate cancer.

Datta K, Muders M, Zhang H, Tindall DJ.

Future Oncol. 2010 May;6(5):823-36. doi: 10.2217/fon.10.33. Review.

40.

FAVL elevation in human tumors disrupts Fanconi anemia pathway signaling and promotes genomic instability and tumor growth.

Zhang J, Zhao D, Park HK, Wang H, Dyer RB, Liu W, Klee GG, McNiven MA, Tindall DJ, Molina JR, Fei P.

J Clin Invest. 2010 May;120(5):1524-34. doi: 10.1172/JCI40908. Epub 2010 Apr 19.

41.

Androgen regulation of gene expression.

Lamont KR, Tindall DJ.

Adv Cancer Res. 2010;107:137-62. doi: 10.1016/S0065-230X(10)07005-3. Review.

PMID:
20399963
42.

Effect of dutasteride on the risk of prostate cancer.

Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS; REDUCE Study Group.

N Engl J Med. 2010 Apr 1;362(13):1192-202. doi: 10.1056/NEJMoa0908127.

43.

Androgen receptor abnormalities in castration-recurrent prostate cancer.

Nacusi LP, Tindall DJ.

Expert Rev Endocrinol Metab. 2009 Sep 1;4(5):417-422.

44.

Differential regulation of steroid nuclear receptor coregulator expression between normal and neoplastic prostate epithelial cells.

Heemers HV, Schmidt LJ, Kidd E, Raclaw KA, Regan KM, Tindall DJ.

Prostate. 2010 Jun 15;70(9):959-70. doi: 10.1002/pros.21130.

45.

New developments in the medical management of prostate cancer.

Kohli M, Tindall DJ.

Mayo Clin Proc. 2010 Jan;85(1):77-86. doi: 10.4065/mcp.2009.0442. Review.

46.

Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression.

Wang D, Montgomery RB, Schmidt LJ, Mostaghel EA, Huang H, Nelson PS, Tindall DJ.

Cancer Res. 2009 Dec 15;69(24):9448-56. doi: 10.1158/0008-5472.CAN-09-1903.

47.

Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81.

Shin S, Kim TD, Jin F, van Deursen JM, Dehm SM, Tindall DJ, Grande JP, Munz JM, Vasmatzis G, Janknecht R.

Cancer Res. 2009 Oct 15;69(20):8102-10. doi: 10.1158/0008-5472.CAN-09-0941. Epub 2009 Sep 29.

48.

Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter.

Msaouel P, Iankov ID, Allen C, Aderca I, Federspiel MJ, Tindall DJ, Morris JC, Koutsilieris M, Russell SJ, Galanis E.

Mol Ther. 2009 Dec;17(12):2041-8. doi: 10.1038/mt.2009.218. Epub 2009 Sep 22.

49.

Deficiencies in Chfr and Mlh1 synergistically enhance tumor susceptibility in mice.

Fu Z, Regan K, Zhang L, Muders MH, Thibodeau SN, French A, Wu Y, Kaufmann SH, Lingle WL, Chen J, Tindall DJ.

J Clin Invest. 2009 Sep;119(9):2714-24. doi: 10.1172/JCI37405. Epub 2009 Aug 17.

50.

Effects of the 5 alpha-reductase inhibitor dutasteride on gene expression in prostate cancer xenografts.

Schmidt LJ, Regan KM, Anderson SK, Sun Z, Ballman KV, Tindall DJ.

Prostate. 2009 Dec 1;69(16):1730-43. doi: 10.1002/pros.21022.

Supplemental Content

Loading ...
Support Center